Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Smatti, Maria K ^a   Yassine, Hadi M ^a   AbuOdeh, Raed ^b   AlMarawani, Asmaa ^c   Taleb, Sara A ^a   Althani, Asmaa A ^a   Nasrallah, Gheyath K ^a  

^a QATAR UNIVERSITY   (Qatar)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c ASPETAR ORTHOPAEDIC AND SPORTS MEDICINE HOSPITAL   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ADULT; AGE; AGED; ARTICLE; BLOOD BUFFY COAT; BLOOD DONOR; BLOOD SAMPLING; CHINA; DNA EXTRACTION; EBV EBNA2 GENE; EGYPTIAN; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; INDIAN; JORDANIAN; LMP 1 GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MOLECULAR GENETICS; NONHUMAN; NORTH CAROLINA; PAKISTANI; PHYLOGENY; QATAR; QATARI; SEROPREVALENCE; SYRIAN; VIREMIA; VIRUS CAPSID; VIRUS GENE; VIRUS STRAIN; YOUNG ADULT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGY;

ADULT; ANTIBODIES, VIRAL; BLOOD DONORS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUPS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; POLYMERASE CHAIN REACTION; QATAR; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 85038408050     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0189033     Document Type: Article

References (74)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. The Lancet. 1964; 283(7335):702–703. https://doi.org/10.1016/s0140-6736(64)91524-7
2. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat Rev Cancer. 2004; 4(10):757–768. https://doi.org/10.1038/nrc1452 PMID: 15510157
3. Kasahara Y, Yachie A. Cell type specific infection of Epstein–Barr virus (EBV) in EBV-associated hemo-phagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol. 2002; 44 (3):283–294. https://doi.org/10.1016/s1040-8428(02)00119-1 PMID: 12467968
4. Tzellos S, Farrell PJ. Epstein-barr virus sequence variation-biology and disease. Pathogens. 2012; 1 (2):156–174. https://doi.org/10.3390/pathogens1020156 PMID: 25436768; PubMed Central PMCID: PMCPMC4235690.
5. Santpere G, Darre F, Blanco S, Alcami A, Villoslada P, Mar Albà M, et al. Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol Evol. 2014; 6(4):846–860. https://doi.org/10.1093/gbe/evu054 PMID: 24682154; PubMed Central PMCID: PMCPMC4104767.
6. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol. 2009; 10(4):321–322. PMID: 19350698.
7. Humme S, Reisbach G, Feederle R, Delecluse HJ, Bousset K, Hammerschmidt W, et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A. 2003; 100(19):10989–10994. https://doi.org/10.1073/pnas.1832776100 PMID: 12947043; PubMed Central PMCID: PMCPMC196914.
8. Epstein Barr Virus Volume 1. Münz C, editor: Springer International Publishing; 2015. 344 p.
9. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr Virus Infections in Healthy Individuals. J Virol. 2003; 77(11):6546–6550. https://doi.org/10.1128/JVI.77.11.6546-6550.2003 PMID: 12743312
10. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci. 2003; 10(5):490–504. doi: 72376. PMID: 12928589.
11. Yakovleva LS, Senyuta NB, Goncharova EV, Scherback LN, Smirnova RV, Pavlish OA, et al. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin]. Mol Biol (Mosk). 2015; 49(5):800–810. https://doi.org/10.7868/S0026898415050213. PMID: 26510598.
12. Saechan V, Settheetham-Ishida W, Kimura R, Tiwawech D, Mitarnun W, Ishida T. Epstein-Barr virus strains defined by the latent membrane protein 1 sequence characterize Thai ethnic groups. J Gen Virol. 2010; 91(8):2054–2061. https://doi.org/10.1099/vir.0.021105–0
13. Saechan V, Mori A, Mitarnun W, Settheetham-Ishida W, Ishida T. Analysis of LMP1 variants of EBV in Southern Thailand: evidence for strain-associated T-cell tropism and pathogenicity. J Clin Virol. 2006; 36(2):119–125. https://doi.org/10.1016/j.jcv.2006.01.018 PMID: 16616610.
14. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr virus infections in healthy individuals. J Virol. 2003; 77(11):6546–6550. https://doi.org/10.1128/JVI.77.11.6546-6550.2003 PMID: 12743312; PubMed Central PMCID: PMCPMC155020.
15. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol. 1991; 72 (Pt 10):2399–2409. https://doi.org/10.1099/0022-1317-72-10-2399 PMID: 1681026.
16. Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virol. 2001; 282 (2):278–287. https://doi.org/10.1006/viro.2001.0828 PMID: 11289810.
17. Gerber P, Walsh JH, Rosenblum EN, Purcell RH. Association of EB-virus infection with the post-perfusion syndrome. Lancet. 1969; 1(7595):593–595. https://doi.org/10.1016/s0140-6736(69)91532-3.PMID: 4180127.
18. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981; 41(11 Pt 1):4253–4261. Epub 1981/11/01. PMID: 6272971.
19. Alfieri C, Tanner J, Carpentier L, Perpête C, Savoie A, Paradis K, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient’s blood and oropharynx. Blood. 1996; 87(2):812–817. PMID: 8555507.
20. Trottier H, Buteau C, Robitaille N, Duval M, Tucci M, Lacroix J, et al. Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfus (Paris). 2012; 52(12):2653–2663. https://doi.org/10.1111/j.1537-2995.2012.03611.x PMID: 22420319
21. Trottier H, Delage G, Hu J, Robitaille N, Buteau C, Tucci M, et al. Detection of Epstein-Barr virus in leu-coreduced blood products. Vox Sang. 2015; 110(2):199–201. https://doi.org/10.1111/vox.12330 PMID: 26383177
22. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008; 8:111. https://doi.org/10.1186/1471-2334-8-111 PMID: 18706107; PubMed Central PMCID: PMCPMC2528010.
23. Dowd JB, Palermo T, Brite J, McDade TW, Aiello A. Seroprevalence of Epstein-Barr virus infection in U. S. children ages 6–19, 2003–2010. PLoS One. 2013; 8(5):e64921. https://doi.org/10.1371/journal.pone.0064921 PMID: 23717674; PubMed Central PMCID: PMCPMC3661547.
24. Nystad TW, Myrmel H. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol. 2007; 38(4):292–297. https://doi.org/10.1016/j.jcv.2007.01.006 PMID: 17336144.
25. Trottier H, Buteau C, Robitaille N, Duval M, Tucci M, Lacroix J, et al. Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfusion. 2012; 52(12):2653–2663. https://doi.org/10.1111/j.1537-2995.2012.03611.x PMID: 22420319.
26. Suntornlohanakul R, Wanlapakorn N, Vongpunsawad S, Thongmee T, Chansaenroj J, Poovorawan Y. Seroprevalence of Anti-EBV IgG among Various Age Groups from Khon Kaen Province, Thailand. Asian Pac J Cancer Prev. 2015; 16(17):7583–7587. PMID: 26625765.
27. Kondo S, Horikawa T, Takeshita H, Kanegane C, Kasahara Y, Sheen TS, et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci. 2004; 95(6):508–513. PMID: 15182432.
28. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350(24):2461–2470. https://doi.org/10.1056/NEJMoa032260 PMID: 15190138.
29. Polz D, Podsiadło Ł, Stec A, Polz-Dacewicz M. Prevalence of EBV genotypes in Polish, Taiwanese and Arabic healthy students and association between genotypes and 30-bp deletion in the LMP-1 gene phylogenetic analysis. Pol J Microbiol. 2014; 63(1):105–109. PMID: 25033670.
30. Sousa H, Silva J, Azevedo L, Pinto-Correia AL, Catarino R, Pinto D, et al. Epstein-Barr virus in healthy individuals from Portugal. Acta Med Port. 2011; 24(5):707–712. Epub 2012/04/25. PMID: 22525621.
31. Hudnall SD, Chen T, Allison P, Tyring SK, Heath A. Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. Transfusion. 2008; 48(6):1180–1187. https://doi.org/10.1111/j.1537-2995.2008.01685.x PMID: 18422852.
32. Vasef MA, Ubaidat MA, Khalidi HS, Almasri NM, Al-Abbadi M, Annab HZ. Association between Epstein-Barr virus and classic Hodgkin lymphoma in Jordan: a comparative study with Epstein-Barr virus-associated Hodgkin lymphoma in North America. South Med J. 2004; 97(3):273–277. https://doi.org/10.1097/01.SMJ.0000090035.09019.8D PMID: 15043335.
33. Makar RR, Saji T, Junaid TA. Epstein-Barr virus expression in Hodgkin’s lymphoma in Kuwait. Pathol Oncol Res. 2003; 9(3):159–165. doi: PAOR.2003.9.3.0159. PMID: 14530808.
34. Audouin J, Diebold J, Nathwani B, Ishak E, Maclennan K, Mueller-Hermelink HK, et al. Epstein-Barr virus and Hodgkin’s lymphoma in Cairo, Egypt. J Hematop. 2010; 3(1):11–18. https://doi.org/10.1007/ s12308-010-0059-3 PMID: 21625283; PubMed Central PMCID: PMC2883908.
35. Al-Diab AI, Siddiqui N, Sogiawalla FF, Fawzy EM. The changing trends of adult Hodgkin’s disease in Saudi Arabia. Saudi Med J. 2003; 24(6):617–622. Epub 2003/07/09. PMID: 12847590.
36. Al-Salam S, John A, Daoud S, Chong SM, Castella A. Expression of Epstein-Barr virus in Hodgkin lymphoma in a population of United Arab Emirates nationals. Leuk Lymphoma. 2008; 49(9):1769–1777. https://doi.org/10.1080/10428190802270894 PMID: 18661399.
37. Al Moustafa AE, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Hum Vaccin Immunother. 2016; 12(7):1936–1939. https://doi.org/10.1080/21645515.2016.1139255 PMID: 27082145; PubMed Central PMCID: PMC4964818.
38. Bel-Air FD. Demography, Migration, and Labour Market in Qatar. Gulf Research Center. 2014; 8(2014).
39. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009; 47(10):3204–3210. https://doi.org/10.1128/JCM. 00164-09 PMID: 19656988; PubMed Central PMCID: PMCPMC2756947.
40. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol. 2012; 1(1):31–43. https://doi.org/10.5501/wjv.v1.i1.31 PMID: 24175209; PubMed Central PMCID: PMCPMC3782265.
41. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980; 77(5):2979–2983. PMID: 6248876; PubMed Central PMCID: PMC349530.
42. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004; 42(8):3381–3387. https://doi.org/10.1128/JCM.42.8.3381-3387.2004PMID: 15297472; PubMed Central PMCID: PMCPMC497621.
43. Farrell PJ. Epstein–Barr Virus Strain Variation. Curr Top Microbiol Immunol: Springer International Publishing; 2015. p. 45–69.
44. Mendes TM, Oliveira LC, Yamamoto L, Del Negro GM, Okay TS. Epstein-Barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings. Braz J Infect Dis. 2008; 12(3):186–191. PMID: 18833401.
45. AbuOdeh RO, Al-Absi E, Ali NH, Khalili M, Al-Mawlawi N, Hadwan TA, et al. Detection and phylogenetic analysis of human pegivirus (GBV-C) among blood donors and patients infected with hepatitis B virus (HBV) in Qatar. J Med Virol. 2015; 87(12):2074–2081. https://doi.org/10.1002/jmv.24289 PMID: 26058920.
46. Magrath IT. African Burkitt’s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991; 13(2):222–246. PMID: 2069232.
47. Chapman AL, Rickinson AB. Epstein-Barr virus in Hodgkin’s disease. Ann Oncol. 1998; 9 Suppl 5:S5–16. PMID: 9926231.
48. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004; 10(3):803–821. PMID: 14871955.
49. Niedobitek G, Herbst H, Young LS, Rowe M, Dienemann D, Germer C, et al. Epstein-Barr virus and carcinomas. Expression of the viral genome in an undifferentiated gastric carcinoma. Diagn Mol Pathol. 1992; 1(2):103–108. PMID: 1342957.
50. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 1992; 140 (4):769–774. Epub 1992/04/01. PMID: 1314023; PubMed Central PMCID: PMCPMC1886378.
51. Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990–2010. Infect Agent Cancer. 2014; 9(1):38. https://doi.org/10.1186/1750-9378-9-38 PMID: 25473414; PubMed Central PMCID: PMC4253616.
52. Henrik H, Jeppe F, M. Chapter 53 The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press Copyright (c) Cambridge University Press 2007; 2007.
53. Lazda VA. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients. Transplant Proc. 2006; 38(10):3404–3405. https://doi.org/10.1016/j.transproceed.2006.10.066 PMID: 17175286.
54. Loutfy SA, Alam El-Din HM, Ibrahim MF, Hafez MM. Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt. Saudi Med J. 2006; 27(8):1139–1145. Epub 2006/08/03. PMID: 16883441.
55. Venkitaraman AR, Lenoir GM, John TJ. The seroepidemiology of infection due to Epstein-Barr virus in southern India. J Med Virol. 1985; 15(1):11–16. PMID: 2981976.
56. Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, et al. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol. 2003; 10(1):78–82. https://doi.org/10.1128/CDLI.10.1.78-82. 2003 PMID: 12522043; PubMed Central PMCID: PMCPMC145280.
57. Balfour HH, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015; 4(2): e33. https://doi.org/10.1038/cti.2015.1 PMID: 25774295; PubMed Central PMCID: PMCPMC4346501.
58. Dunmire SK, Hogquist KA, Balfour HH. Infectious Mononucleosis. Curr Top Microbiol Immunol. 2015; 390(Pt 1):211–240. https://doi.org/10.1007/978-3-319-22822-8_9 PMID: 26424648; PubMed Central PMCID: PMCPMC4670567.
59. Bauer G. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab. 2001; 47(5–6):223–230. Epub 2001/06/19. PMID: 11405600.
60. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res. 1981; 41(11 Pt 1):4222–4225. PMID: 6272966.
61. Guerrero-Ramos A, Patel M, Kadakia K, Haque T. Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis. Clin Vaccine Immunol. 2014; 21(6):817–823. https://doi.org/10.1128/CVI.00754-13 PMID: 24695777; PubMed Central PMCID: PMCPMC4054247.
62. de Ory F, Guisasola ME, Sanz JC, García-Bermejo I. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin Vaccine Immunol. 2011; 18(3):444–448. https://doi.org/10.1128/CVI.00486-10 PMID: 21191077; PubMed Central PMCID: PMCPMC3067387.
63. Vilibic-Cavlek T, Ljubin-Sternak S, Kos L, Mlinaric-Galinovic G. The role of IgG avidity determination in diagnosis of Epstein-Barr virus infection in immunocompetent and immunocompromised patients. Acta Microbiol Immunol Hung. 2011; 58(4):351–357. https://doi.org/10.1556/AMicr.58.2011.4.10 PMID: 22207292.
64. Nishiwaki M, Fujimuro M, Teishikata Y, Inoue H, Sasajima H, Nakaso K, et al. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi’s sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay. J Med Virol. 2006; 78(12):1635–1642. https://doi.org/10.1002/jmv.20748 PMID: 17063511.
65. Traore L, Tao I, Bisseye C, Djigma F, Ouermi D, Zohoncon T, et al. Molecular diagnosis of cytomegalovirus, Epstein-Barr virus and Herpes virus 6 among blood donors in Ouagadougou, Burkina Faso. BMC Infect Dis. 2014; 14(Suppl 2):P99. https://doi.org/10.1186/1471-2334-14-s2-p99
66. Bauer CC, Aberle SW, Popow-Kraupp T, Kapitan M, Hofmann H, Puchhammer-Stöckl E. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol. 2005; 75(1):54–58. https://doi.org/10.1002/jmv.20237 PMID: 15543583.
67. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. 2000; 38(2):712–715. Epub 2000/02/03. PMID: 10655372; PubMed Central PMCID: PMCPMC86184.
68. Gan YJ, Sullivan JL, Sixbey JW. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis. 1994; 170(2):436–439. PMID: 8035032.
69. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003; 41(12):5419–5428. https://doi.org/10.1128/JCM.41.12.5419-5428.2003 PMID: 14662920; PubMed Central PMCID: PMCPMC308959.
70. Chan KH, Ng MH, Seto WH, Peiris JS. Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection. J Clin Microbiol. 2001; 39(11):4152–4154. https://doi.org/10.1128/JCM.39.11.4152-4154;2001 PMID: 11682546; PubMed Central PMCID: PMCPMC88503.
71. Gartzonika C, Vrioni G, Priavali E, Georgios P, Levidiotou S. Utility of Real-Time PCR in the Diagnosis of Primary Epstein-Barr Virus Infection. Medical Microbiology & Diagnosis; 2012.
72. Kwok H, Chan KW, Chan KH, Chiang AK. Distribution, persistence and interchange of Epstein-Barr virus strains among PBMC, plasma and saliva of primary infection subjects. PLoS One. 2015; 10(3): e0120710. https://doi.org/10.1371/journal.pone.0120710 PMID: 25807555; PubMed Central PMCID: PMCPMC4373854.
73. Srivastava G, Wong KY, Chiang AK, Lam KY, Tao Q. Coinfection of multiple strains of Epstein-Barr virus in immunocompetent normal individuals: reassessment of the viral carrier state. Blood. 2000; 95 (7):2443–2445. Epub 2000/03/25. PMID: 10733520.
74. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virol. 1999; 261(1):79–95. https://doi.org/10.1006/viro.1999.9855 PMID: 10441557.